With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.32 which represents a decrease of $-1.45 or -2.60% from the prior close of $55.77. The stock opened at $55.88 and ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Jefferies analyst Akash Tewari maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.

On the buy write, if BMY closes above $56 at expiration on, you will be assigned and earn $2.55 per share on $53.45 per share at risk, or 4.77%. Over a holding period of 29 days, the annualized return ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...